Cargando…

Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study

BACKGROUND: The treatment of ulcerative colitis (UC) patients with moderate to severe inflammatory activity with anti-tumor necrosis factor alpha (TNFα) antibodies leads to a clinical remission rate of 10% after 8 weeks of therapy. However, it must be taken into account that patient selection in cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drabik, Attyla, Sturm, Andreas, Blömacher, Margit, Helwig, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2016
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942680/ https://www.ncbi.nlm.nih.gov/pubmed/27352964 http://dx.doi.org/10.2196/resprot.5791

Ejemplares similares

Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study
por: Cording, Jimmi, et al.
Publicado: (2019)

Diagnostic Value of Fecal Calprotectin in Patient with Ulcerative Colitis
por: Zamani, Hamed, et al.
Publicado: (2013)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale
por: Drabik, Attyla, et al.
Publicado: (2014)

Usefulness of fecal immunochemical test and fecal calprotectin for detection of active ulcerative colitis
por: Kim, Dong Ju, et al.
Publicado: (2018)

Fecal Calprotectin and Clinical Disease Activity in Pediatric Ulcerative Colitis
por: Kolho, Kaija-Leena, et al.
Publicado: (2013)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS
por: Chiu, E, et al.
Publicado: (2022)

Percutaneous Bioelectric Current Stimulation in the Treatment of Chronic Achilles Tendinopathy: Protocol for a Double-Blind, Placebo-Controlled Randomized Multicenter Trial
por: Schröder, Philipp, et al.
Publicado: (2022)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
por: Ryu, Dae Gon, et al.
Publicado: (2019)

Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis
por: Urushikubo, Jun, et al.
Publicado: (2018)

Clinical Value of Fecal Calprotectin in Predicting Mucosal Healing in Patients With Ulcerative Colitis
por: Chen, Fang, et al.
Publicado: (2021)

Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
por: Kamat, Nagesh, et al.
Publicado: (2022)

Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
por: Chang, Ji Young, et al.
Publicado: (2018)

Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis
por: Kawashima, Kousaku, et al.
Publicado: (2016)

Optimal cut‐off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?
por: Jha, Ashish Kumar, et al.
Publicado: (2018)

Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis
por: Malvão, Ludimilla dos Reis, et al.
Publicado: (2021)

Associations between Pouchitis and Fecal Calprotectin after Restorative Proctocolectomy in Patients with Ulcerative Colitis
por: Uchino, Motoi, et al.
Publicado: (2023)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease
por: Gauss, Annika, et al.
Publicado: (2016)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome
por: Kalantari, Hamid, et al.
Publicado: (2015)

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis
por: Kristensen, Vendel, et al.
Publicado: (2017)

Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis
por: Ye, Xiaoqi, et al.
Publicado: (2021)

The Utility of Fecal Calprotectin in the Diagnosis and Management of Microscopic Colitis
por: Songtanin, Busara, et al.
Publicado: (2023)

Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis
por: Ma, Rong, et al.
Publicado: (2020)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis
por: Hu, Tingpeng, et al.
Publicado: (2023)

Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis
por: Hosseini, Seyed Vahid, et al.
Publicado: (2015)

Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type
por: Sonoyama, Hiroki, et al.
Publicado: (2019)

Fecal calprotectin as an indicator in risk stratification of pouchitis following ileal pouch–anal anastomosis for ulcerative colitis
por: Li, Rui-Bin, et al.
Publicado: (2023)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
por: Iborra, Marisa, et al.
Publicado: (2020)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fpgtvsqfp9d65oe57uqofus557